Showing results (11-20 of 23) with videos related to

Sort By:
Pageof 3
Frontiers in Oncology|January 2, 2023
Post-operative ctDNA monitoring in stage I colon cancer: A case reportStephanie L Alden, Harmeet Dhani, Charuta C Palsuledesai, et al.
Journal for Immunotherapy of Cancer|July 10, 2019
Rescue therapy for patients with anti-PD-1-refractory Merkel cell carcinoma: a multicenter, retrospective case seriesJaclyn LoPiccolo, Megan D Schollenberger, Sumia Dakhil, et al.
JTO Clinical and Research Reports|March 18, 2026
Brief Report: Multi-Institution Real-World Analysis Evaluating Safety, Efficacy, and ctDNA Dynamics After Tarlatamab in Patients With Previously Treated SCLC and LCNECGraeme Fenton, Annie L Zhang, Sharon Zhong, et al.
Cancer Medicine|February 23, 2018
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanomaSamuel Rosner, Erica Kwong, Alexander N Shoushtari, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2023
Five-Year Clinical Outcomes after Neoadjuvant Nivolumab in Resectable Non-Small Cell Lung CancerSamuel Rosner, Joshua E Reuss, Marianna Zahurak, et al.
The New England Journal of Medicine|March 9, 2012
Immunologic correlates of the abscopal effect in a patient with melanomaMichael A Postow, Margaret K Callahan, Christopher A Barker, et al.
Lung Cancer (Amsterdam, Netherlands)|December 10, 2025
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANSBingnan Zhang, Laura Alder, Samuel Rosner, et al.
Journal for Immunotherapy of Cancer|June 10, 2022
Peripheral blood immune cell dynamics reflect antitumor immune responses and predict clinical response to immunotherapyMichael Hwang, Jenna Vanliere Canzoniero, Samuel Rosner, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2024
Divergent Clinical and Immunologic Outcomes Based on STK11 Co-mutation Status in Resectable KRAS-Mutant Lung Cancers Following Neoadjuvant Immune Checkpoint BlockadeSamuel Rosner, Sydney Connor, Khaled Sanber, et al.
Biorxiv : the Preprint Server for Biology|July 10, 2023
Elucidating the heterogeneity of immunotherapy response and immune-related toxicities by longitudinal ctDNA and immune cell compartment tracking in lung cancerJoseph C Murray, Lavanya Sivapalan, Karlijn Hummelink, et al.
Pageof 3